Journal of Molecular Neuroscience

, Volume 50, Issue 2, pp 360–367 | Cite as

Effect of Genetic Polymorphism +294T/C in Peroxisome Proliferator-Activated Receptor Delta on the Risk of Ischemic Stroke in a Tunisian Population

  • Khouloud Chehaibi
  • Mohamed Yahia Hrira
  • Mustapha Rouis
  • Mohamed Najah
  • Imen Jguirim-Souissi
  • Samir Nouira
  • Mohamed Naceur Slimane


PPARδ +294T/C polymorphism was investigated in diabetics, in normolipidemic healthy controls, in dyslipidemic and nondyslipidemic coronary artery disease patients but never in ischemic stroke patients. The aim of this study was to explore, for the first time, the relationship between the genetic polymorphism of PPARδ and the risk of ischemic stroke among patients with diabetes. The study group consisted of 196 patients with ischemic stroke and 192 controls. Plasma concentrations of total cholesterol, triglycerides, low-, and high-density lipoprotein did not differ significantly between subjects carrying the TT genotype and those carrying the CC/TC genotype in both ischemic stroke patients (with or without diabetes) and control groups. The +294C allele (CC + CT genotypes) as compared with TT genotypes was found to be higher in total ischemic stroke patients than in controls. On the other hand, no interaction between diabetes and PPAR +294T/C polymorphism on the risk of ischemic stroke was found (p = 0.089). The PPARδ +294T/C polymorphism was associated with the risk of ischemic stroke in Tunisian subjects. This polymorphism has no influence on plasma lipoprotein concentrations and body mass index either in healthy subjects or in ischemic stroke patients with or without diabetes both in males and females.


PPARδ Polymorphism Diabetes Ischemic stroke 



We would like to thank Dr. Nouira Samir of the Emergency Department at Fattouma Bourguiba University Hospital in Monastir (Tunisia) for recruiting stroke patients and for his help. A part of this work was supported by a grant from “Ministère de l'Enseignement Supérieur, de la Recherche Scientifique et de la Technologie-Tunisie.”


  1. Aberle J, Hopfer I, Beil FU, Seedorf U (2006a) Association of the T + 294C polymorphism in PPAR d with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3:108–111PubMedCrossRefGoogle Scholar
  2. Aberle J, Hopfer I, Beil FU, Seedorf U (2006b) Association of peroxisome proliferator-activated receptor delta + 294 T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes (Lond) 30:1709–1713CrossRefGoogle Scholar
  3. Allen CL, Bayraktutan U (2008) Risk factors for ischaemic stroke. Int J Stroke 3:105–116PubMedCrossRefGoogle Scholar
  4. Arsenijevic D, de Bilbao F, Plamondon J et al (2006) Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β-deficient mice. J Cereb Blood Flow Metab 26:433–445PubMedCrossRefGoogle Scholar
  5. Barak Y, Liao D, He W, Ong ES et al (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303–308PubMedCrossRefGoogle Scholar
  6. Barish GD, Atkins AR, Downes M et al (2008) PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis. PNAS 105:4271–4276PubMedCrossRefGoogle Scholar
  7. Burch LR, Donnelly LA, Doney ASF et al (2010) Peroxisome Proliferator-Activated Receptor-delta Genotype Influences Metabolic Phenotype and May Influence Lipid Response to Statin Therapy in Humans: A Genetics of Diabetes Audit and Research Tayside Study. J Clin Endocrinol Metab 95:1830–1837PubMedCrossRefGoogle Scholar
  8. Cardon LR, Palmer LJ (2003) Population stratification and spurious allelic association. Lancet 361:598–604PubMedCrossRefGoogle Scholar
  9. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ (2004) Effects of PPARa, g and d haplotypes on plasma levels of lipids and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenet 14:61–71CrossRefGoogle Scholar
  10. Colhoun HM, McKeigue PM, Davey SG (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865–872PubMedCrossRefGoogle Scholar
  11. Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6:149–161PubMedCrossRefGoogle Scholar
  12. Dressel U, Allen TL, Pippal JB, Rohde PR et al (2003) The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17:2477–2493PubMedCrossRefGoogle Scholar
  13. Flossmann E, Schulz UG, Rothwell PM (2004) Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 35:212–227PubMedCrossRefGoogle Scholar
  14. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. ClinChem 18:499–502Google Scholar
  15. Gilde AJ, van der Lee KA, Willemsen PH et al (2003) Peroxisome proliferator-activated receptor (PPAR) aandPPARb/d, but not PPARg, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518–524PubMedCrossRefGoogle Scholar
  16. Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W (2005) The peroxisome proliferator-activated receptor delta +294 T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183:336–341PubMedCrossRefGoogle Scholar
  17. Grarup N, Albrechtsen A, Ek J et al (2007) Variation in the PPAR delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 50:1201–1208PubMedCrossRefGoogle Scholar
  18. Hankey GJ (2006) Potential new risk factors for ischemic stroke: what is their potential? Stroke 37:2181–2188PubMedCrossRefGoogle Scholar
  19. Hu C, Jia W, Fang Q et al (2006) Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet Med 23(12):1307–1312PubMedCrossRefGoogle Scholar
  20. Iadecola C, Davisson RL (2008) Hypertension and cerebrovascular dysfunction. Cell Metab 7:476–484PubMedCrossRefGoogle Scholar
  21. Iwashita A, Muramatsu Y, Yamazaki T et al (2007) Neuroprotective efficacy of the peroxisome proliferators-activated receptor delta selective agonists in vitro and in vivo. J Pharmacol Exp Ther 320:1087–1096PubMedCrossRefGoogle Scholar
  22. Jguirim-Souissi I, Jelassi A, Hrira Y et al (2010) + 294 T/C polymorphism in the PPAR- d gene is associated with risk of coronary artery disease in normolipidemic Tunisians. Genet Mol Res 9:1326–1333PubMedCrossRefGoogle Scholar
  23. Kim HJ, Kim MY, Jin et al (2009) Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/ Smad3. Circ Res 105:16–24PubMedCrossRefGoogle Scholar
  24. Kirshner HS (2009) Differentiating ischemic stroke subtypes: risk factors and secondary prevention. J Neurol Sci 279:1–8PubMedCrossRefGoogle Scholar
  25. Lee CH, Chawla A, Urbiztondo N et al (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302:453–457PubMedCrossRefGoogle Scholar
  26. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J et al (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 473:333–336PubMedCrossRefGoogle Scholar
  27. Liou JY, Lee S, Ghelani D et al (2006) Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26:1481–1487PubMedCrossRefGoogle Scholar
  28. Lu L, Wu Y, Qi Q et al (2012) Associations of Type 2 Diabetes with Common Variants in PPARD and the Modifying Effect of Vitamin D among Middle-Aged and Elderly Chinese. PLoS One 7(4):e34895PubMedCrossRefGoogle Scholar
  29. Michalik L, Desvergne B, Tan NS et al (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta mutant mice. J Cell Biol 154:799–814PubMedCrossRefGoogle Scholar
  30. Nikitin AG, Chistiakov DA, Minushkina LO, Zateyshchikov DA, Nosikov VV (2010) Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Hear Vessel 25:229–236CrossRefGoogle Scholar
  31. Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311PubMedCrossRefGoogle Scholar
  32. Peters JM, Lee SS, Li W et al (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 20:5119–5128PubMedCrossRefGoogle Scholar
  33. Pialat JB, Cho TH, Beuf O et al (2007) MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR Biomed 20:335–342PubMedCrossRefGoogle Scholar
  34. Piqueras L, Reynolds AR, Hodivala-Dilke KM et al (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27:63–69PubMedCrossRefGoogle Scholar
  35. Rival Y, Beneteau N, Taillandier T et al (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143–151PubMedCrossRefGoogle Scholar
  36. Robitaille J, Gaudet D, Perusse L, Vohl MC (2006 Sep 5). Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta - 87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond)Google Scholar
  37. Robitaille J, Gaudet D, Pérusse L, Vohl MC (2007) Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator activated receptor-delta - 87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 31:411–417CrossRefGoogle Scholar
  38. Schulz UG, Rothwell PM (2003) Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 34:2050–2059PubMedCrossRefGoogle Scholar
  39. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613–2618PubMedCrossRefGoogle Scholar
  40. Shin HD, Park BL, Kim LH et al (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 53(3):847–851PubMedCrossRefGoogle Scholar
  41. Skogsberg J, Kannisto K, Roshani L et al (2000) Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med 6:73–81PubMedGoogle Scholar
  42. Skogsberg J, Kannisto K, Cassel TN, Hamsten A et al (2003a) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637–643PubMedCrossRefGoogle Scholar
  43. Skogsberg J, McMahon AD, Karpe F, Hamsten A et al (2003b) Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 254:597–604PubMedCrossRefGoogle Scholar
  44. Tan NS, Michalik L, Noy N, Yasmin R et al (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15:3263–3277PubMedCrossRefGoogle Scholar
  45. Tan NS, Michalik L, Di-Poi N, Desvergne B et al (2004) Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. Biochem Soc Trans 32:97–102PubMedCrossRefGoogle Scholar
  46. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus ADA (1998) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 22( Suppl. 1):S5–S19Google Scholar
  47. Villegas R, Williams S, Gao Y et al (2011) Variation and type 2 diabetes in middle age Chinese women. Ann Hum Genet 75(5):621–629PubMedCrossRefGoogle Scholar
  48. Vosper H, Patel L, Graham TL et al (2001) The peroxisome proliferator-activated receptor_ promotes lipid accumulation in human macrophages. J Biol Chem 276:44258–44265PubMedCrossRefGoogle Scholar
  49. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2(10):294CrossRefGoogle Scholar
  50. Wei X-L, Yin R-X, Miao L, Wu D-F (2011) The peroxisome proliferator-activated receptor delta +294T>C polymorphism and alcohol consumption on serum lipid levels. Lipids Health Dis 10:242PubMedCrossRefGoogle Scholar
  51. Welch JS, Ricote M, Akiyama TE et al (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 100:6712–6717PubMedCrossRefGoogle Scholar
  52. Yilmaz-Aydogan H, Kurnaz O, Kurt O et al (2011) Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358:355–363PubMedCrossRefGoogle Scholar
  53. Yılmaz-Aydogan H, Kucukhuseyin O, Kurnaz O et al (2012) Investigation of polymorphic variants of PPARD and APOE Genes in Turkish Coronary Heart Disease Patients. DNA Cell Biol 31:867–875PubMedCrossRefGoogle Scholar
  54. Yin KJ, Deng Z, Hamblin M et al (2010) Peroxisome proliferator-activated receptor delta regulation of mir-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci 30:6398–6408PubMedCrossRefGoogle Scholar
  55. Yin KJ, Zhen D, Milton H, Jifeng Z, Chen EY (2011) Vascular PPARδ protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol 31:574–581PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Khouloud Chehaibi
    • 1
  • Mohamed Yahia Hrira
    • 2
  • Mustapha Rouis
    • 3
  • Mohamed Najah
    • 1
  • Imen Jguirim-Souissi
    • 1
  • Samir Nouira
    • 4
  • Mohamed Naceur Slimane
    • 1
  1. 1.Research Unit: UR 12ES09 Dyslipidemia and Atherogenesis, Faculty of MedicineMonastirTunisia
  2. 2.ResearchUnit: UR 07/06, Faculty of PharmacyMonastirTunisia
  3. 3.UMR 7079 Physiology and PhysiopathologyUniversity Pierre and Marie CurieParis 6France
  4. 4.Emergency DepartmentCHU Fattouma BourguibaMonastirTunisia

Personalised recommendations